Literature DB >> 21162623

Vibrio cholerae: lessons for mucosal vaccine design.

Anne L Bishop1, Andrew Camilli.   

Abstract

The ability of Vibrio cholerae to persist in bodies of water will continue to confound our ability to eradicate cholera through improvements to infrastructure, and thus cholera vaccines are needed. We aim for an inexpensive vaccine that can provide long-lasting protection from all epidemic cholera infections, currently caused by O1 or O139 serogroups. Recent insights into correlates of protection, epidemiology and pathogenesis may help us design improved vaccines. This notwithstanding, we have come to appreciate that even marginally protective vaccines, such as oral whole-cell killed vaccines, if widely distributed, can provide significant protection, owing to herd immunity. Further efforts are still required to provide more effective protection of young children.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21162623      PMCID: PMC3036168          DOI: 10.1586/erv.10.150

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  183 in total

Review 1.  Delivery systems: a vaccine strategy for overcoming mucosal tolerance?

Authors:  Jamie F S Mann; Reinaldo Acevedo; Judith Del Campo; Oliver Pérez; Valerie A Ferro
Journal:  Expert Rev Vaccines       Date:  2009-01       Impact factor: 5.217

2.  Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motility.

Authors:  Anne L Bishop; Stefan Schild; Bharathi Patimalla; Brian Klein; Andrew Camilli
Journal:  Infect Immun       Date:  2010-08-02       Impact factor: 3.441

3.  Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam.

Authors:  D D Trach; P D Cam; N T Ke; M R Rao; D Dinh; P V Hang; N V Hung; D G Canh; V D Thiem; A Naficy; B Ivanoff; A-M Svennerholm; J Holmgren; J D Clemens
Journal:  Bull World Health Organ       Date:  2002       Impact factor: 9.408

4.  Studies on interventions to prevent eltor cholera transmission in urban slums.

Authors:  B C Deb; B K Sircar; P G Sengupta; S P De; S K Mondal; D N Gupta; N C Saha; S Ghosh; U Mitra; S C Pal
Journal:  Bull World Health Organ       Date:  1986       Impact factor: 9.408

5.  Protective effect on infections with Vibrio cholerae in suckling mice caused by the passive immunization with milk of immune mothers.

Authors:  A Ujiye; K Kobari
Journal:  J Infect Dis       Date:  1970-05       Impact factor: 5.226

6.  An Fc receptor structurally related to MHC class I antigens.

Authors:  N E Simister; K E Mostov
Journal:  Nature       Date:  1989-01-12       Impact factor: 49.962

7.  Lack of cross-protection against diarrhea due to Vibrio cholerae O139 (Bengal strain) after oral immunization of rabbits with V. cholerae O1 vaccine strain CVD103-HgR.

Authors:  M J Albert; K Alam; M Ansaruzzaman; F Qadri; R B Sack
Journal:  J Infect Dis       Date:  1994-01       Impact factor: 5.226

8.  Acute dehydrating disease caused by Vibrio cholerae serogroups O1 and O139 induce increases in innate cells and inflammatory mediators at the mucosal surface of the gut.

Authors:  F Qadri; T R Bhuiyan; K K Dutta; R Raqib; M S Alam; N H Alam; A-M Svennerholm; M M Mathan
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

9.  Complexity of rice-water stool from patients with Vibrio cholerae plays a role in the transmission of infectious diarrhea.

Authors:  Eric J Nelson; Ashrafuzzaman Chowdhury; Jason B Harris; Yasmin A Begum; Fahima Chowdhury; Ashraful I Khan; Regina C Larocque; Anne L Bishop; Edward T Ryan; Andrew Camilli; Firdausi Qadri; Stephen B Calderwood
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-16       Impact factor: 11.205

10.  Host-induced epidemic spread of the cholera bacterium.

Authors:  D Scott Merrell; Susan M Butler; Firdausi Qadri; Nadia A Dolganov; Ahsfaqul Alam; Mitchell B Cohen; Stephen B Calderwood; Gary K Schoolnik; Andrew Camilli
Journal:  Nature       Date:  2002-06-06       Impact factor: 49.962

View more
  21 in total

1.  Rapid effects of a protective O-polysaccharide-specific monoclonal IgA on Vibrio cholerae agglutination, motility, and surface morphology.

Authors:  Kara J Levinson; Magdia De Jesus; Nicholas J Mantis
Journal:  Infect Immun       Date:  2015-02-09       Impact factor: 3.441

2.  A monoclonal antibody that targets the conserved core/lipid A region of lipopolysaccharide affects motility and reduces intestinal colonization of both classical and El Tor Vibrio cholerae biotypes.

Authors:  Kara J Levinson; Danielle E Baranova; Nicholas J Mantis
Journal:  Vaccine       Date:  2016-10-20       Impact factor: 3.641

Review 3.  Vaccines against human diarrheal pathogens: current status and perspectives.

Authors:  Nathalie Böhles; Nathalie Böhles; Kim Busch; Kim Busch; Michael Hensel; Michael Hensel
Journal:  Hum Vaccin Immunother       Date:  2014-05-26       Impact factor: 3.452

4.  Immunity Provided by an Outer Membrane Vesicle Cholera Vaccine Is Due to O-Antigen-Specific Antibodies Inhibiting Bacterial Motility.

Authors:  Zhu Wang; David W Lazinski; Andrew Camilli
Journal:  Infect Immun       Date:  2016-12-29       Impact factor: 3.441

5.  The Live Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae.

Authors:  Leslie M Mayo-Smith; Jakub K Simon; Wilbur H Chen; Douglas Haney; Michael Lock; Caroline E Lyon; Stephen B Calderwood; Beth D Kirkpatrick; Mitchell Cohen; Myron M Levine; Marc Gurwith; Jason B Harris
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

6.  Neutrophils are essential for containment of Vibrio cholerae to the intestine during the proinflammatory phase of infection.

Authors:  Jessica Queen; Karla J Fullner Satchell
Journal:  Infect Immun       Date:  2012-05-21       Impact factor: 3.441

7.  Plant-based production of two chimeric monoclonal IgG antibodies directed against immunodominant epitopes of Vibrio cholerae lipopolysaccharide.

Authors:  Kara J Levinson; Samantha R Giffen; Michael H Pauly; Do H Kim; Ognian Bohorov; Natasha Bohorova; Kevin J Whaley; Larry Zeitlin; Nicholas J Mantis
Journal:  J Immunol Methods       Date:  2015-04-09       Impact factor: 2.303

8.  The utility of human challenge studies in vaccine development: lessons learned from cholera.

Authors:  Debbie-Ann T Shirley; Monica A McArthur
Journal:  Vaccine (Auckl)       Date:  2011-10

9.  Vibrio cholerae Outer Membrane Vesicles Inhibit Bacteriophage Infection.

Authors:  Tamara Reyes-Robles; Rebecca S Dillard; Lynne S Cairns; Cecilia A Silva-Valenzuela; Max Housman; Afsar Ali; Elizabeth R Wright; Andrew Camilli
Journal:  J Bacteriol       Date:  2018-07-10       Impact factor: 3.490

Review 10.  Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens.

Authors:  Yuchen Fan; James J Moon
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.